ArticleToxins2026
Biotransformation Is an Effective Mechanism for Modulating the Biological Toxicity of Nodularin (NODR).
Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biotransformation of nodularin (NOD) is one of the critical strategies for regulating their biological toxicity. To investigate the effects and mechanisms of the biotransformation pathway, this study synthesized six biotransformation products of nodulein-R (NODR-BTPs) and evaluated their inhibitory effects on protein phosphatase 1 (PP1) through protein phosphatase inhibition assays. The inhibitory effects of NODR-BTPs diminished as the molecular weight and polarity of the introduced biological thiols increased, indicating that biotransformation is an efficient mechanism for modulating the biological toxicity of NODR. Through ligand replacement and molecular docking techniques, the potential regulatory mechanisms underlying the primary interaction processes between NODR-BTPs and PP1 were further elucidated. The introduced biological thiols improved the hydrogen bonding for Glu
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.